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Exuberant fibroblast activity compromises 
lung function via ADAMTS4
David F. Boyd1, E. Kaitlynn Allen1, Adrienne G. Randolph2,3, Xi-zhi J. Guo1, Yunceng Weng4, 
Catherine J. Sanders1, Resha Bajracharya1, Natalie K. Lee5, Clifford S. Guy1, Peter Vogel6, 
Wenda Guan4, Yimin Li4, Xiaoqing Liu4, Tanya Novak2,3, Margaret M. Newhams2,  
Thomas P. Fabrizio5, Nicholas Wohlgemuth5, Peter M. Mourani7, PALISI Pediatric Intensive 
Care Influenza (PICFLU) Investigators*, Thomas N. Wight8, Stacey Schultz-Cherry5, 
Stephania A. Cormier9,10, Kathryn Shaw-Saliba11, Andrew Pekosz12, Richard E. Rothman11, 
Kuan-Fu Chen13,14, Zifeng Yang4, Richard J. Webby5, Nanshan Zhong4, Jeremy Chase Crawford1 
& Paul G. Thomas1 ✉
Severe respiratory infections can result in acute respiratory distress syndrome 
(ARDS)1. There are no effective pharmacological therapies that have been shown to 
improve outcomes for patients with ARDS. Although the host inflammatory response 
limits spread of and eventually clears the pathogen, immunopathology is a major 
contributor to tissue damage and ARDS1,2. Here we demonstrate that respiratory viral 
infection induces distinct fibroblast activation states, which we term extracellular 
matrix (ECM)-synthesizing, damage-responsive and interferon-responsive states.  
We provide evidence that excess activity of damage-responsive lung fibroblasts  
drives lethal immunopathology during severe influenza virus infection. By producing 
ECM-remodelling enzymes—in particular the ECM protease ADAMTS4—and 
inflammatory cytokines, damage-responsive fibroblasts modify the lung 
microenvironment to promote robust immune cell infiltration at the expense of lung 
function. In three cohorts of human participants, the levels of ADAMTS4 in the lower 
respiratory tract were associated with the severity of infection with seasonal or avian 
influenza virus. A therapeutic agent that targets the ECM protease activity of 
damage-responsive lung fibroblasts could provide a promising approach to 
preserving lung function and improving clinical outcomes following severe 
respiratory infections.
Respiratory infections are a leading cause of morbidity and mortal-
ity3. These infections can result in ARDS with pulmonary oedema 
and hypoxia, causing mild to severe respiratory failure1. Much of 
the lung damage induced by viral infection is a result of infiltrating 
immune cells, which kill infected and bystander cells4. Defining the 
mechanisms that alter the balance between pathogen clearance and 
immunopathology may enable identification of strategies to improve 
outcomes following ARDS2. Therapeutic targets include components 
of the lung ECM, which provides structural support that is critical 
for lung function and tissue-specific signals to coordinate immune 
responses5.
The ECM consists of structural proteins as well as proteases and 
glycosidases that degrade or modify the ECM6. Upon lung injury, ECM 
proteases are upregulated and remodel the ECM, facilitating the migra-
tion of immune cells to sites of inflammation5,7. Non-immune lung cells, 
including epithelial cells, endothelial cells and fibroblasts, coordi-
nate immune responses and directly mediate lung function8. Through 
their remodelling activity, specific cell populations can influence the 
outcome of infection and long-term sequelae, as has been described for 
myofibroblasts and lung fibrosis9. The role of lung stromal cell popula-
tions in coordinating host responses to active respiratory infections 
has received less attention than their role in late-stage repair following 
pathogen clearance. While there is extensive literature on how immune 
cells regulate the host response to respiratory viral infection8, there is 
less information on the heterogeneity and role of non-haematopoietic 
cells.
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Stromal responses to influenza infection
We sorted live, CD45− lung cells from mice 0, 1, 3 and 6 days after infec-
tion with influenza A virus and performed single-cell gene-expression 
profiling (scGEX) identifying three main populations: fibroblasts, epi-
thelial cells and endothelial cells (Fig. 1a, b, Extended Data Fig. 1a, b). 
High levels of viral mRNA, indicative of productive infection, were 
detected primarily in type I pneumocytes, ciliated epithelial cells and 
type II pneumocytes (Extended Data Fig. 1c). Fibroblasts were particu-
larly dynamic, with multiple transcriptional states emerging following 
infection (Fig. 1c, d, Extended Data Fig. 1d). To assess the pathways active 
in each cluster, we performed gene-set enrichment analysis (GSEA), 
comparing each cluster to a putative baseline cluster (cluster 5) that 
was present before infection with few differentially expressed genes 
(Fig. 1c, Extended Data Fig. 2a). We identified three primary functional 
groups on the basis of gene expression: resting, ECM-synthesizing 
and inflammatory (Fig. 1c, Extended Data Fig. 2a). ECM-synthesizing 
fibroblasts (ESFibs) were enriched for genes encoding ECM structural 
proteins, but lacked inflammatory signatures (Fig. 1d, Extended Data 
Fig. 2a). Inflammatory fibroblasts exhibited high expression of genes 
involved in type I interferon, interleukin-6 (IL-6) or NF-κB signalling, 
whereas resting fibroblasts lacked strong enrichment for pathways 
involved in either inflammatory responses or synthesis of ECM proteins. 
(Fig. 1e, Extended Data Fig. 2a).
Among inflammatory fibroblasts, we identified two distinct 
activation states, damage-responsive fibroblasts (DRFibs) and 
interferon-responsive fibroblasts (IRFibs) (Fig. 1d). DRFibs were 
enriched for pathways involved in tissue-damage responses, 
including NF-κB signalling and hypoxia, whereas IRFibs were enriched 
for type-I-interferon-responsive pathways (Fig. 1e, f, Extended Data 
Fig. 2b). Analysis of five human lung biopsies identified fibroblast acti-
vation states analogous to those defined in mouse lungs (Extended Data 
Fig. 2c) with clusters enriched for ECM synthesis, NF-κB signalling and 
type-I interferon signalling (Extended Data Fig. 2c, d).
To validate these fibroblast activation states, we identified genes 
encoding surface-protein markers that were enriched in DRFibs and 
IRFibs in mouse and human lungs (Fig. 1f, Extended Data Figs. 2d, 
3a, b). Upregulation of Itga5 and downregulation of Cd9 defined the 
DRFib transcriptional program, whereas upregulation of Bst2 and 
expression of Cd9 defined IRFibs (Fig. 1g, Extended Data Fig. 3a). In 
mice, DRFibs increased in frequency and number over the course of 
infection, reaching a peak around 12 days (Fig. 1g, h, Extended Data 
Fig. 3c, d). IRFibs emerged rapidly, by day 3, and gradually decreased 
in frequency (Fig. 1h). ITGA5hiCD9lo fibroblasts expressed high levels 
of DRFib signature genes (Lox and Adamts4), whereas ITGA5loCD9hi 
fibroblasts exhibited a resting phenotype, with low expression of 
infection-induced genes (Extended Data Fig. 3e, f). Primary lung 
fibroblasts stimulated with IL-1 and TNF, cytokines known to drive 
NF-κB signalling, acquired a surface phenotype with higher ITGA5 
expression, indicative of a damage-responsive activation state 
(Extended Data Fig. 3g). Analysis of human lung biopsies identified 
fibroblasts that exhibited surface phenotypes similar to those in 
mouse lungs. Activated fibroblasts with a damage-responsive pro-
file (ITGA5hiCD9lo) were present in donors who died of respiratory 
failure, but were noticeably absent from healthy donors (Extended 
Data Fig. 4a, b).
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Fig. 1 | Single-cell gene-expression profiling of 
CD45− cells during severe influenza A virus 
infection. a, Schematic of sample collection for 
scGEX. SSC, side scatter. b, t-distributed stochastic 
neighbour embedding (t-SNE) projection of mouse 
lung cells based on scGEX. Data from all time points 
and mice were aggregated (n = 5 (0, 1 and 3 dpi), and 
n = 4 (6 dpi)). Approximately 40,800 individual cells 
are represented in the figure. c, t-SNE projection of 
mouse mesenchymal cells expressing Col1a2.  
d, t-SNE projection of mouse mesenchymal cells at 
different time points after infection. e, Summary of 
GSEA comparing all cells in each cluster (cluster 1, 
n = 1,188; cluster 2, n = 1,123; cluster 4, n = 892; 
cluster 6, n = 749; cluster 8, n = 681). βcat, β-catenin; 
resp., response; ROS, reactive oxygen species; sig., 
signalling; SMCs, smooth muscle cells.  
f, Expression of key genes in mouse lung 
mesenchymal cells. g, Kinetics of fibroblast 
activation states. Representative flow cytometry 
for ITGA5, CD9 and BST2 staining. h, Frequency of 
DRFib and IRFib activation states during infection 
(0 dpi, n = 5; 3 dpi, n = 4; 6 dpi, n = 3; 9 dpi, n = 4; 12 dpi, 
n = 4; 21 dpi, n = 5). Data are mean ± s.e.m.
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Regulation of fibroblast activation
We next sought to identify the upstream stimuli that regulate fibroblast 
activation states. We tested whether in vitro infection of normal human 
bronchial epithelial cells (NHBEs) with human seasonal (H3N2) or avian 
viruses (H5N6 or H7N9) was sufficient to drive inflammatory transcrip-
tional programs in human lung fibroblasts in co-culture (Fig. 2a). Infec-
tion of NHBEs induced expression in fibroblasts of genes enriched in 
inflammatory states, including genes encoding cytokines (IL6) and 
several matrix proteases (ADAMTS4, MMP3 and MMP13). We also tested 
the ability of individual cytokines and influenza viruses to stimulate 
these transcriptional programs in respiratory cells cultured on their 
own (Fig. 2a, monoculture), comparing them with nasal wash cells 
from patients infected with influenza virus, which comprise primarily 
immune cells10. These data demonstrated cell-type-specific expression 
of ECM-related genes (Extended Data Fig. 5a). In contrast to NHBEs, 
fibroblasts were highly responsive to stimulation with IL-1 cytokines 
and TNF, and ECM-related genes were broadly upregulated (Fig. 2a, 
Extended Data Fig. 5b, c). Nasal wash cells exhibited low levels of expres-
sion of ECM-related genes encoding both structural proteins and matrix 
proteases. However, nasal wash and epithelial cells also exhibited high 
levels of IL1A, IL1B and TNF expression, indicating that they probably 
provide immune signals to fibroblasts to regulate ECM-related gene 
expression (Extended Data Fig. 5a).
ECM proteases in activated fibroblasts
We sought to determine whether any individual protease has a funda-
mental effector role underlying productive and nonproductive lung 
repair. We assessed the regulation of ECM-related genes in mouse lung 
homogenates collected at different times during influenza virus infec-
tion (Fig. 2b). Detection of ECM proteases and tissue inhibitors of metal-
loproteinases (TIMPs) by enzyme-linked immunosorbent assay (ELISA) 
in the bronchoalveolar lavage (BAL) fluid corresponded with the kinet-
ics of gene expression in lung homogenates (Extended Data Fig. 5d). 
Among the tested ECM proteases, the expression of ADAMTS4—one 
of the enzymes that degrade the proteoglycan versican11—was the earli-
est to be induced, and its expression continued throughout the repair 
stage (Fig. 2b). On the basis of scGEX analyses, expression of Adamts4 
was restricted to non-immune, stromal cells (Fig. 2c). We next sorted 
immune and non-immune populations before and after infection. Before 
infection, Adamts4 gene expression was restricted to fibroblasts and 
endothelial cells. After infection, a significant upregulation of Adamts4 
expression was observed only in fibroblasts, which we conclude account 
for the bulk of Adamts4 expression in infected lungs (Fig. 2d).
To determine the specificity of ADAMTS4 gene expression in human 
lung disease, we performed a meta-analysis of publicly available scGEX 
datasets from seven studies of pulmonary fibrosis12–14, interstitial lung 
disease15, allergy and asthma16,17, and viral infection (with severe acute 
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respiratory syndrome coronavirus 2 (SARS-CoV-2))18 (Extended Data 
Fig. 6 a). For reference, we included a study of rheumatoid arthritis, 
a disease driven by inflammatory fibroblasts19. ADAMTS4-positive 
cells included mesenchymal cells and endothelial cells, with a smaller 
number of epithelial and immune cells (Extended Data Fig. 6b, c). 
Fibroblasts with the highest levels of ADAMTS4 expression exhibited 
an activated phenotype with enriched expression of genes associated 
with DRFibs (Extended Data Fig. 6d). Analysis of a subset of data from 
a study by Habermann et al.12 indicated that expression of ADAMTS4 
was markedly increased in inflammatory lung disease compared with 
healthy control tissue (Extended Data Fig. 6e). Mesenchymal cells 
expressed the highest levels of ADAMTS4 on a per-cell basis—at least an 
order of magnitude higher than other cell types, including endothelial 
cells (Extended Data Fig. 6f). Per-cell levels of ADAMTS4 were low in 
epithelial and immune cells and did not increase in diseased lungs 
compared to controls.
To determine how fibroblast responses were organized anatomi-
cally, we performed spatial transcriptomics on mouse lung sections 
collected at the peak of respiratory distress (10 days post-infection 
(dpi)). Unsupervised clustering of transcriptional profiles identified 
areas of the lung (red, 0) that overlapped with regions of interstitial 
inflammation (Fig. 2e, Extended Data Fig. 7a). Genes associated with 
DRFibs, including Itga5, Lox and Adamts4, were enriched in these 
regions (Fig. 2e, Extended Data Fig. 7b–d). Adamts4 expression was 
restricted to areas of interstitial inflammation near the alveoli. Expres-
sion of DRFib-associated genes was reduced or absent from bronchial 
regions (green, 2), areas of dense lymphoid infiltration (teal, 3), and 
from areas of normal alveolar parenchyma (yellow, 1). Together, these 
data place DRFibs expressing Adamts4 in the distal airways at a critical 
inflection point when hosts either begin to recover or their condition 
worsens.
ADAMTS4 promotes lethal immunopathology
To determine the contribution of ADAMTS4 to infection outcome, we 
challenged Adamts4−/− and Adamts4+/+ mice with a lethal dose of influ-
enza A virus. Adamts4−/− mice exhibited improved survival compared 
with Adamts4+/+ controls, independently of the viral burden in the lungs 
(Fig. 3a, b, Extended Data Fig. 8a, b). Neither the frequency nor total 
number of infected cells differed substantially between Adamts4−/− and 
Adamts4+/+ mice, although there were modest cell-type-specific differ-
ences (Extended Data Fig. 8c). In contrast to wild-type mice, Adamts4−/− 
mice were able to maintain lung function, as measured by arterial oxygen 
saturation, at 6 dpi (Fig. 3c). At 9 dpi, Adamts4−/− mice exhibited a sig-
nificant decrease in immune cell infiltration and alveolar inflammation, 
with less extensive lung tissue damage (Fig. 3d). Consistent with reduced 
damage, Adamts4−/− mice had less total protein in BAL fluid compared 
with Adamts4+/+ controls and lower levels of key inflammatory mediators 
(TNF and MCP-1) in lung homogenates (Extended Data Fig. 8d, e). These 
differences in tissue damage translated to improved lung mechanics in 
Adamts4−/− mice, as measured by airway resistance and dynamic lung 
compliance (Fig. 3e, Extended Data Fig. 8f).
We examined the consequences of ADAMTS4 deficiency on the lev-
els of versican, a major substrate of ADAMTS4. During inflammation, 
versican is an important component of the provisional matrix, a loose 
extracellular network that directs cell migration, proliferation and 
differentiation20; its function depends on its degradation state and 
interaction with other ECM proteins. Compared with wild-type mice, 
Adamts4−/− mice exhibited higher levels of intact versican in areas of 
lung remodelling after infection (Extended Data Fig. 9a, b). The levels of 
other known versicanases were not changed after infection in wild-type 
or Adamts4−/− mice (Extended Data Fig. 9c). As CD8+ T cells are one of 
the main drivers of immunopathology during infection with influenza A 
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Fig. 3 | ADAMTS4 promotes lethal immunopathology during influenza A 
virus infection in mice. a, Survival curves following challenge with influenza A 
virus (Adamts4+/+ (WT), n = 33; Adamts4−/− (KO), n = 23; log-rank test, two-sided; 
data pooled from five independent experiments). b, Representative images of 
lung from infected mice and quantification of viral spread. Areas of active 
infection are outlined in red (3 dpi: WT, n = 6; KO, n = 5, and 6 dpi: WT, n = 5; KO, 
n = 6). c, Arterial oxygen saturation (SpO2) at 3 and 6 dpi (WT, n = 5; KO, n = 5).  
d, Representative images and histological scores at 9 dpi with sublethal 
challenge (WT, n = 9; KO, n = 9). NP, viral nucleoprotein immunohistochemistry. 
e, Airway resistance with sublethal challenge (uninfected: WT, n = 8; KO, n = 3, 
and infected: WT n = 8; KO, n = 9). RI, resistance. f, Quantification of IFNγ+CD8+ 
T cells from lungs collected at 9 dpi (WT, n = 10; KO, n = 9). g, Quantification of 
major histocompatibility complex (MHC) tetramer+CD8+ T cells in the lung at 
9 dpi (WT, n = 10; KO, n = 10) containing peptides from polymerase basic protein 
1 (PB1), polymerase acid protein (PA) and nucleoprotein. h, Representative 
images of CD3 (green), intact versican (red) and DAPI (blue) staining in lung 
sections and quantification of CD3+ cells. Three to four fields of view imaged 
from each individual mouse (uninfected, n = 3; WT, n = 5; KO, n = 4). Scale bar,  
50 μm. i, CD8+ T cell migration in the presence of Adamts4 wild-type and 
knockout fibroblasts. The number of migrated cells is normalized to uncoated 
control for each genotype (n = 6 biologically independent samples per group). 
j, CD8+ T cell migration with different fibroblast activation states (n = 4 
biologically independent samples per group). PBS, vehicle control (uncoated 
membrane). Unless otherwise indicated, data are pooled from two 
independent experiments. Data are mean ± s.e.m. Groups were compared 
using a two-sided Mann–Whitney U test.
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virus4,21, we assessed CD8+ T cell responses in the lungs at 9 dpi, the time 
point with peak T cell responses and lung damage. Adamts4−/− mice had 
a significantly lower percentage of IFNγ-producing CD8+ T cells (Fig. 3f, 
Extended Data Fig. 9d, e). The percentage of influenza A virus-specific 
CD8+ T cells did not differ between wild-type and Adamts4−/− mice, 
indicating that Adamts4−/− mice were able to mount influenza A 
virus-specific T cell responses similar to those of wild-type mice (Fig. 3g, 
Extended Data Fig. 9f). We observed significantly fewer T cells in lung 
sections of Adamts4−/− mice compared with Adamts4+/+ mice, with T cells 
being largely absent from areas with high intact versican (Fig. 3h). We 
next tested whether fibroblast-derived ADAMTS4 could promote T cell 
migration across a versican barrier (Fig. 3i). Activated CD8+ T cells 
migrated across uncoated and versican-coated membranes with nearly 
identical efficiency in the presence of ADAMTS4-sufficient fibroblasts. 
By contrast, migration across a versican-coated membrane was reduced 
by more than 40% in the presence of ADAMTS4-deficient fibroblasts. 
Consistent with DRFibs being the main producers of ADAMTS4, DRFibs 
promoted migration across a versican barrier, whereas migration was 
inhibited in the presence of resting fibroblasts and IRFibs (Fig. 3j), 
highlighting the distinct functions of the different fibroblast activa-
tion states.
ADAMTS4 and severe influenza in humans
We next investigated the contribution of ADAMTS4 in the human respir-
atory tract to severe influenza virus infection in the Paediatric Intensive 
Care Influenza (PICFLU) network. We analysed samples of endotracheal 
aspirate (ETA) collected within 72 h of admission to intensive care from 
a multicentre cohort of 84 paediatric patients with influenza virus infec-
tion (Extended Data Fig. 10a). Levels of ECM proteases and TIMPs were 
analysed in the context of inflammatory mediators22. Controlling for 
age, ADAMTS4 was positively correlated with levels of IL-1B and TNF, 
which we identified as upstream regulators of ADAMTS4 expression, 
and with IFNγ, which was expressed at a higher frequency in CD8+ T cells 
in ADAMTS4 sufficient mice during influenza A virus infection (Fig. 4a). 
We next tested whether levels of ADAMTS4 in ETA were associated 
with the severity of influenza-related disease using three indicators: 
prolonged multiple organ dysfunction syndrome (PrMODS) or death, 
prolonged acute hypoxic respiratory failure (PrAHRF) or death, and 
fewer than ten ventilator-free days (VFDs) (Extended Data Fig. 10b). 
In each case, the log of the ADAMTS4 concentration was significantly 
associated with disease severity outcome after controlling for age, 
gender and baseline health status (PrMODS/death: odds ratio = 3.14, 
P = 0.003; PrAHRF/death: odds ratio = 2.27, P = 0.018; VFD < 10: odds 
ratio = 2.95, P = 0.027; Fig. 4b, Extended Data Fig. 10c).
To determine whether these findings translated to adults, we ana-
lysed samples from two distinct, primarily adult cohorts: one from 
Taipei, representing moderate-to-severe cases of seasonal influenza 
(37 individuals) and one from Guangzhou, representing severe cases 
of H7N9 avian influenza (16 individuals) and seasonal H1N1 influenza 
(14 individuals) (Extended Data Fig. 10d). We tested samples from mul-
tiple respiratory compartments (ETA, sputum and BAL fluid). Individu-
als from the Taiwan cohort were sampled at a single time point after 
symptom onset, whereas most of those from the Guangzhou cohort 
were sampled at multiple time points.
A correlation matrix of the same analytes indicated similar patterns of 
ECM protease, TIMP and cytokine regulation in the cohorts of primarily 
adult patients with influenza (Fig. 4c). We tested whether ADAMTS4 was 
associated with a particular respiratory compartment, including 131 
nasal wash samples from the Taiwan cohort. ADAMTS4 was detectable 
at very low levels in 5% (6 out of 131) of nasal wash samples tested, but at 
higher frequencies and concentrations in each of the lower respiratory 
tract (LRT) compartments, suggesting that the source of ADAMTS4 is 
localized to the LRT during infection (Extended Data Fig. 10e).
Finally, we tested whether ADAMTS4 is a predictor of disease severity 
during adult infection with influenza virus. To make the data compa-
rable with the PICFLU cohort, we focused on the earliest available ETA 
sample, including only the first BAL fluid or sputum sample (in that 
order) when an ETA sample was not available. The log of the ADAMTS4 
concentration was significantly associated with severity of disease, 
as determined by fewer than ten VFDs (odds ratio = 1.95, P = 0.020) 
(Fig. 4d). By combining samples from all three cohorts, the log of the 
ADAMTS4 concentration was associated with VFD values of less than 
ten, including age and gender as potential covariates (odds ratio = 2.22, 
P = 3.1 × 10−5) (Extended Data Fig. 10f). On the basis of these results, 
we propose that the level of ADAMTS4 protein in the LRT is a strong 
predictor of hypoxic respiratory failure and mortality following severe 
influenza virus infection across a wide range of ages.
Discussion
Surviving a severe respiratory infection is dependent on a delicate 
balance between mounting a sufficient immune response to clear the 
infection and maintaining lung function despite immunity-induced 
tissue damage. Fibroblasts are located at the interface of the epithe-
lial site of infection and the endothelial entry point of immune cells, 
well placed to integrate inflammatory signals and coordinate immune 
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responses through modification of the local tissue environment23. In 
this study we provide evidence that lung fibroblasts are critical for 
coordinating immune responses at the site of viral infection in the 
tissue, starting soon after infection and continuing throughout the 
repair process. During infection, lung fibroblasts respond to dam-
aged epithelial cells, transmit inflammatory signals and modify the 
ECM to generate a tissue environment that promotes robust immune 
responses to infection. Recent studies have described both protective24 
and pathogenic25–27 roles for ECM proteases in the host response to 
influenza virus. Whereas these studies identified immune cells as the 
primary sources of ECM proteases, the data presented here indicate 
that inflammatory fibroblasts integrate danger signals from epithe-
lial cells and resident immune cells to produce diverse inflammatory 
cytokines, ECM components and degradative enzymes that modify the 
local tissue environment. In mice, deficiency of ADAMTS4 activity in the 
lung preserves intact ECM-localized versican and modulates immune 
cell migration into areas of infection. Previous studies have indicated 
that intact versican is able to suppress cytotoxic T cell responses and 
inhibit migration24,28–30. Our data from studies with human participants 
suggest that ADAMTS4 is an important determinant of influenza dis-
ease severity across a wide age range. High ADAMTS4 concentrations 
in endotracheal samples from the paediatric cohort—collected soon 
after admission to intensive care—were strong predictors of PrAHRF 
and PrMODS, and in all cohorts, high ADAMTS4 concentrations in LRT 
samples were associated with fewer ventilator-free days. The role of 
ADAMTS4 in promoting excessive immunopathology also warrants 
further investigation in the context of other severe respiratory infec-
tions, including infection with severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2).
Understanding the basis for activation phenotypes in fibroblasts will 
be a critical future direction for these studies. Determining whether 
these are true differentiation lineages or if the cells can revert back to 
a resting state will require the development of precise lineage-tracing 
models. Currently, there are no effective therapeutic agents to treat 
severe complications of respiratory viral infections such as ARDS, and 
treatment is supportive1. We propose that targeting the ECM protease 
activity of damage-responsive fibroblasts could provide clinical ben-
efits, by both limiting excessive inflammation and maintaining the 
integrity of lung tissue, and that ADAMTS4 activity may be a suitable 
target for therapeutic intervention.
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Methods
No statistical methods were used to predetermine sample size. The 
experiments were not randomized. The investigators were not blinded 
to allocation during experiments. The investigators were blinded to 
outcome assessment in some experiments as indicated below.
Mice
B6.129P2-Adamts4tm1Dgen/J (Adamts4−/−) mice were obtained from 
Jackson Laboratories. These mice were backcrossed with C57BL/6J 
mice for at least 10 generations to generate congenic Adamts4−/− and 
Adamts4+/+ mice. Mice were housed at 68 °F, 12 h light/dark cycle and 
approximately 45% humidity.
Studies involving mice were approved by the St Jude Children’s 
Research Hospital Committee on Care and Use of Animals. All mice 
that were tested in this study were bred and maintained at the St Jude 
Children’s Research Hospital under specific-pathogen free conditions.
Single-cell RNA sequencing
Whole lungs were collected from pathogen-free C57BL/6 mice 
(Taconic Biosciences) at 0, 1, 3, 6 and 21 days after initial infection. 
Four or five mice for each time point were infected with 2500 EID50 of 
mouse-adapted influenza A/Puerto Rico/8/1934 (PR8) virus intranasally 
in 30 μl of 1× PBS31. Lungs were perfused with 10 ml cold 1× PBS injected 
into the right ventricle of the heart and then minced and digested in 
lung digestion buffer containing 400 U ml−1 collagenase I (Worthington 
Biochemical Corporation) and 50 U ml−1 of DNaseI (ThermoFisher) in 
Hank’s balanced salt solution (HBSS) for 75 min at 37 °C. Digested lungs 
were filtered through a 100-μm cell strainer and washed with HBSS. 
Red blood cell were lysed and resuspended at 1 × 106 cells per ml. Cells 
were incubated with Ghost Dye Violet 510 (Tonbo) (1:100 dilution) and 
APC anti-mouse CD45.2 (clone 104, Biolegend) (1:100 dilution) for 
30 min at room temperature. Live, CD45− cells were sorted into 1.7-ml 
microfuge tubes and then centrifuged at 400g for 5 min. Cells were 
then incubated with PE-conjugated anti-mouse H-2 antibody (1:100, 
clone M1/42, Biolegend) for 30 min on ice.
Human lung biopsy samples from de-identified, deceased patients 
were obtained through the National Disease Research Interchange 
(NDRI). Cause of death of these patients was unrelated to respiratory 
tract infection or lung damage, and they did not have a history of 
tobacco use or lung cancer. Fresh 5 cm × 5 cm × 5 cm lung biopsy samples 
were minced and digested in 400 U ml−1 of collagenase I (Worthington 
Biochemical Corporation) and 50 U ml−1 of DNaseI (ThermoFisher) in 
HBSS for 90 min at 37 °C. Lung samples were first filtered through sterile 
gauze and then through a 100-μm cell strainer and washed with HBSS, 
then red blood cell lysis was performed. Single-cell suspensions of total 
lung cells were frozen in freeze medium (90% FBS, 10% DMSO) at a con-
centration of 5 × 106 cells per ml. For single-cell RNA sequencing using 
10X Genomics, vials of cells were thawed and incubated with Ghost Dye 
Violet 510 (Tonbo) (1:100 dilution) and APC anti-human CD45 (1:200) 
for 30 min at room temperature. Live, CD45− cells and live, CD45+ cells 
were sorted into 1.7-ml microfuge tubes and then centrifuged at 400g 
for 5 min. Following sorting, cells were incubated with PE anti-human 
β2 microglobulin (1:100) and PE anti-human CD45 (1:100) antibodies 
for 30 min on ice.
For both mouse and human lung samples, cells were washed three 
times and then incubated with custom-designed hashtag oligos (HTO) 
conjugated to anti-PE antibodies (Thunder-Link PLUS Oligo Conju-
gation System, Expedeon), unique for each individual mouse. After 
incubation, cells were washed three times and then pooled within each 
time point. Approximately 25,000 cells per sample were loaded onto 
the Chromium controller (10X Genomics) to partition single cells into 
gel beads. Single-cell transcriptomic libraries were generated using 
the 5′ Gene Expression Kit (V2, 10X Genomics) according to the manu-
facturer’s instructions with the addition of primers to amplify HTOs 
during cDNA amplification. Sequencing was performed on the Illumina 
NovaSeq to generate approximately 500 million reads per sample.
Single-cell gene-expression analyses
The 10X gene-expression data were first processed using CellRanger 
(v.3.0.2, 10X Genomics). Human data were processed using version 
3.0.0 of the GRCh38 10X reference, whereas mouse data were processed 
using the mm10 reference altered to include the PR8 influenza genome. 
CellRanger was then used to aggregate species-specific samples, nor-
malizing by the number of mapped reads per identified cell. Normalized 
feature-barcode matrices including both gene expression and HTO 
counts were then imported into Seurat (v.3.0.0.900) for downstream 
analysis32.
Data were first filtered by excluding any gene that was not present in 
at least 0.1% of total called cells and then by excluding cells that exhib-
ited extremes in the species-specific distributions of: the number of 
genes expressed (mouse: <100 or >5,550; human: <100 or >4,500), the 
number of mRNA molecules (mouse: >30,000; human: >20,000), or 
the percentage of expression owed to mitochondrial genes (mouse and 
human: >7.5%). Gene-expression counts were log-normalized using 
a scaling factor of 1 × 104, variable features targeted for downstream 
analysis were identified using the ‘vst’ method with default parameters, 
and cell-cycle scores were generated for each cell using markers identi-
fied elsewhere33. Gene expression was then scaled to regress out the 
effects of total transcript expression, percent of mitochondrial expres-
sion, and cell cycle scores. For first-pass analyses of entire datasets, 
we selected principal components (PCs) visually using an elbow plot 
of the PC standard deviations (mouse: 25; human: 19). These PCs were 
then used for t-SNE dimensionality reduction and cell clustering with 
Seurat’s shared-nearest-neighbour modularity algorithm to broadly 
characterize the cell types in the entirety of each sample. Individual 
cell subsets were annotated using known markers from the literature.
For more detailed analyses of fibroblast differentiation states, we 
generated a subset of the identified fibroblast clusters, identified the 
top variable features within this subset, and re-scaled those data as 
described above. For the mouse fibroblast data, we also regressed out 
the effects of days post infection to more precisely characterize the 
variance among fibroblast clusters and distinguish cellular responses to 
experimental infection. After repeating principal component analysis, 
principal components were scored for significance (false-discovery rate 
(FDR)-adjusted P < 0.05) using random permutations as implemented 
in Seurat. Differential gene expression was assessed among clusters for 
all genes expressed in at least 1% of cells within a cluster using a general-
ized linear hurdle model that incorporates both expression frequency 
and abundance34. For pairwise cluster comparisons of interest, genes 
were then ranked as a function of the product of their average log fold 
change, the absolute value of the difference in percent expression, and 
the inverse of the scaled, FDR-adjusted P value. These gene-rank lists 
were then analysed using preranked GSEA35.
Meta-analysis of publicly available human single-cell 
gene-expression datasets
Human single-cell gene-expression data from published reports 
(Extended Data Fig. 6a) were obtained from online data repositories. 
From ref. 17 we were only able to obtain data from four healthy con-
trols, as other data, including the data from patients with asthma, 
were not publicly available. Each dataset was filtered to exclude cells 
with more than 20% mitochondrial content, fewer than 200 genes, 
or fewer than 200 RNA molecules before being normalized, scaled, 
and assessed for variable features using the SCTransform wrapper in 
Seurat32. Focal analyses of specific datasets were conducted on these 
resulting data objects. We also compiled the datasets for meta-analysis 
using reference-based integration with 3,000 integration features, with 
data from ref. 12 as the reference, again using the SCTransform normali-
zation method. Downstream analyses were focused on the subset of 
cells that contained at least one ADAMTS4 transcript. Dimensionality 
reduction and clustering were conducted as described previously, but 
in this case using the integration assay. Differential gene-expression 
analyses were conducted on the RNA assay of the integrated object 
using default parameters in Seurat.
Flow cytometry for lung stromal cells and FACS
At the indicated time point after infection, lungs were perfused with 10 ml 
cold 1× PBS injecting into the right ventricle of the heart and then 
minced and digested in lung digestion buffer containing 400 U ml−1 
of collagenase I (Worthington Biochemical Corporation) and 50 U ml−1 
of DNaseI (ThermoFisher) in HBSS for 30 min at 37 °C. Digested lungs 
were filtered through a 100-μm cell strainer and washed with HBSS. Red 
blood cell lysis was performed, and cells were washed and resuspended 
in fluorescence-activated cell sorting (FACS) buffer (1% FBS and 2 mM 
EDTA in 1× PBS). CD45+ cells were depleted using mouse CD45 Micro-
beads (Miltenyi) according to the manufacturer’s instructions. In brief, 
cells were incubated with microbeads for 15 min on ice, washed with 
FACS buffer, and resuspended in 500 μl of buffer. CD45+ cells were then 
depleted using a Miltenyi LS column, and the flow through (CD45− cells) 
were collected. For antibody staining, 1 × 106 cells were plated and then 
incubated with Fc block for 10 min at room temperature. Cells were 
washed one time with FACS buffer and then resuspended in 100 μl of 
an antibody cocktail containing the following: Ghost Dye Violet 510 
(1:100), BV605 anti-mouse CD45 (1:200), BV421 anti-mouse EpCAM 
(1:200), PerCP/Cy5.5 anti-mouse CD31 (1:200), FITC anti-mouse BST2 
(1:100), PE anti-mouse CD9 (1:100) and APC anti-mouse CD49e (1:100). 
Cells were incubated with the antibody cocktail for 30 min at room tem-
perature and then washed twice with FACS buffer before resuspending 
in a final volume of 150 μl. For single-cell suspensions from human lung 
biopsy samples, cells were washed one time with FACS buffer and then 
resuspended in 100 μl of an antibody cocktail containing the following: 
Ghost Dye Violet 510 (1:100), BV605 anti-human CD45 (1:100), BV785 
anti-human EpCAM (1:100), APC Fire 750 anti-human CD31 (1:100), PE/
Cy7 anti-human CD140a (1:100), APC anti-human CD49e (1:100) and 
PE anti-human CD9 (1:100). Cells were incubated with the antibody 
cocktail for 30 min at room temperature and then washed twice with 
FAC buffer before resuspending in a final volume of 150 μl. Cells were 
analysed using a BD LSRII Fortessa and BD FACSDIVA software (Becton 
Dickinson). Data were analysed using FlowJo software (FlowJo).
High-throughput quantitative PCR
For in vitro stimulation of primary mouse lung fibroblasts, fibroblasts 
were isolated from C57BL6/J. Lungs were collected, minced, and then 
digested in lung digestion buffer containing 0.1% collagenase I (Wor-
thington Biochemical Corporation) and 2.4 U ml−1 dispase (Thermo 
Fisher) for 90 min at 37 °C. Digested lungs were filtered through a 
100-μm cell strainer and then washed with 15 ml of 0.05 M EDTA in 1× 
PBS. Cells were centrifuged at 400g for 10 min and then resuspended 
in complete Dulbecco’s modified Eagle medium (cDMEM) and plated 
in a T75 tissue-culture flask (Corning). For cytokine and virus stimula-
tions, 2 × 105 cells were plated in each well of a 24-well plate 24 h before 
stimulation. Fibroblasts were stimulated with the following mouse 
cytokines: IL-1B (10 ng ml−1), IL-1A (10 ng ml−1), IL-33 (10 ng ml−1), IL-18 
(10 ng ml−1), TNF (200 ng ml−1), IFNα (1,000 U ml−1), IL-6 (40 ng ml−1), 
TGFβ (2 ng ml−1), IL-17A (50 ng ml−1), IL-27 (50 ng ml−1), and GM-CSF 
(40 ng ml−1). For the virus stimulations, cells were infected at a mul-
tiplicity of infection (MOI) of 2. Virus inoculum was incubated with 
the cells for 1 h at 37 °C. The following influenza viruses were used for 
the stimulations: A/Puerto Rico/8/1934 (PR8), A/California/04/2009 
(CA09) and A/Perth/16/09 (Perth). The supernatant was removed, and 
cells were washed three times with cDMEM. The wells were replenished 
with 1 ml of cDMEM, and the cells were incubated at 37 °C for 24 h. To 
collect BAL fluid, a catheter was inserted into the trachea, and 3 ml of 
1× PBS was used to wash the lungs. BAL fluid was centrifuged at 400g 
for 5 min to pellet cells, and then the cells were resuspended in 350 μl 
Trizol reagent.
For co-culture experiments, normal human lung fibroblasts (Lonza) 
were plated at a density of 2,500 cells per cm2 in the basal chamber of a 
24-well plate and cultured in fibroblast growth medium (Lonza) over-
night at 37 °C and 5% CO2. NHBEs were seeded at a density of 10,000 
cells per cm2 in 12-mm Transwell inserts (Corning) coated with human 
placental collagen and then added to plates containing fibroblasts. 
Co-cultures were cultured in bronchial epithelial growth medium 
(BEGM) (Lonza) at 37 °C and 5% CO2 for 7–10 days. Co-cultures were 
then taken to the air–liquid interface and basolateral medium was 
exchanged for medium consisting of 50% DMEM and 50% BEGM sup-
plemented with the BEGM BulletKit (Lonza). Medium was changed 
every 2–3 days until the cells were fully differentiated (2–3 weeks). For 
infections, NHBEs were inoculated at a MOI of 2 using the following 
influenza A virus strains: H3N2 A/Perth/16/09, H5N6 A/Oriental Mag-
pie Robin/Hong Kong/6154/2015, and H7N9 A/Hong Kong/125/2017. 
Infections with avian strains were performed in an ABSL3+ facility.
For monoculture experiments, NHBEs from a single donor were 
plated in 24-well Transwell plates (Corning) and cultured in bronchial 
epithelial basal medium (BEBM) (Lonza) supplemented with bovine 
pituitary extract, insulin, hydrocortisone, gentamicin-amphotericin, 
transferrin, triiodothyronine, epinephrine, epidermal growth factor 
and retinoic acid until wells were confluent and cells formed tight junc-
tions. Supernatant was then removed from the apical side of the Tran-
swell and cells were taken into the air–liquid interface for 2–3 weeks. 
NHBEs were then stimulated with the following human cytokines add-
ing each factor to medium in the basal chamber: IL-1B (10 ng ml−1), IL-1A 
(10 ng ml−1), IL-33 (10 ng ml−1), IL-18 (10 ng ml−1), TNF (200 ng ml−1), IFNα 
(1,000 U ml−1), IL-6 (40 ng ml−1), TGF-β (2 ng ml−1), IL-17A (50 ng ml−1), IL-27 
(50 ng ml−1), and GM-CSF (40 ng ml−1). For virus stimulations, cells were 
infected at an MOI of 2. Virus inoculum was incubated with the cells in 
the apical chamber for 1 h at 37 °C. The supernatant was removed, and 
cells were washed three times with BEBM, and incubated at 37 °C for 24 h. 
Normal human bronchial fibroblasts (NHBFs) (Matek) were plated in 
24-well plates at a density of 2 × 105 cells per well and cultured in cDMEM. 
NHBFs were stimulated with the cytokines and viruses listed above. 
Following incubation, the supernatant was removed and cells were col-
lected in 350 μl Trizol Reagent (Thermo Fisher). RNeasy spin columns 
(Qiagen) were then used to isolate RNA from the samples according to 
the manufacturer’s instructions. Following RNA isolation, the amount 
of RNA input was normalized (200 ng), and cDNA was generated using 
the iScript cDNA synthesis kit (Biorad). cDNA was then prepared for 
quantitative PCR (qPCR) using the Fluidigm Biomark (Fluidigm). Data 
were collected using the Fluidigm Biomark data collection software 
(Fluidigm). Exon-spanning qPCR primers were designed to target a 
panel of 96 ECM-related genes for humans (Supplementary Table 1) 
and mice (Supplementary Table 2).
For whole lung homogenates from mice, lungs were collected at 0, 1, 
3, 6, 9, 12, 15, 30 and 40 days after infection. C57BL6/J mice were infected 
with 2500 EID50 PR8. Whole lungs were dissected and homogenized in 
750 μl Trizol reagent using the TissueLyser II (Qiagen). RNA was isolated 
according to the manufacturer’s protocol.
Spatial transcriptomics
C57BL/6J ( Jackson Laboratories) were infected intranasally with 2,500 
50% egg infective dose (EID50) of influenza A virus PR8 in 30 μl of 1× 
PBS. Lungs were dissected from the mice 10 days after infection. Sec-
tions obtained from four distinct mice were imaged and processed for 
spatially resolved gene expression using the Visium Spatial Transcrip-
tomics kit (10x Genomics). Lungs were inflated with 300 μl of 50% OCT 
and 50% PBS v/v and immediately snap-frozen in OCT using isopentane 
that was cooled in a liquid nitrogen bath. For each lung, the same left 
lobe was collected and stored at −80 °C until cryosectioning. For cryo-
sectioning, samples were equilibrated to −22 °C. Exploratory sections 
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were stained with a fluorescent lectin and DAPI to determine areas of 
immune infiltration and remodelling, and then blocks were trimmed to 
5 × 5 mm to encompass normal and remodelled areas before sectioning 
directly onto the spatial transcriptomics kit slide. Tissue permeabiliza-
tion was optimized at 12 min on independent lung sections. Libraries 
were sequenced on the Illumina NovaSeq platform at 28 × 120 base 
pairs, and resulting data were processed using SpaceRanger (v.1.0.0, 
10X Genomics) with manual alignment of fiducial markers, manual 
tissue identification, and r2-length trimmed to 91 base pairs. Down-
stream analyses were conducted with Seurat (v.3.1.4.9901)32.
Adamts4−/− and Adamts4+/+ survival experiments
Mice were anaesthetized with 2,2,2-tribromoethanol by intraperitoneal 
injection and infected intranasally with 6,000 EID50 of PR8 in 30 μl 1× 
PBS. Following infection, mice were monitored twice daily and their 
weight was recorded. Mice were euthanized if they become severely 
moribund based on body index score and substantial weight loss31. 
Righting reflex of severely moribund mice was assessed to determine 
whether immediate euthanasia was necessary. Mice that lost more than 
20% of their body weight were placed on their backs, and if unable to 
right themselves within 10 s, were euthanized. Mice were identified by 
ear tag numbers, and investigators assessing morbidity were blinded 
to the genotype.
Plaque titres
BAL fluid was used to obtain viral titres inoculating Madin–Darby 
Canine Kidney (MDCK) cells. MDCKs were obtained from and authenti-
cated by the American Type Culture Collection (ATCC). The cells were 
not tested for mycoplasma contamination. MDCKs were plated in 6-well 
tissue culture plates at a density of 4 × 105 cells per well. Twenty-four 
hours after plating, cells were washed three times with 1× PBS and then 
incubated with 1 ml of BAL fluid, after six tenfold dilutions in serum-free 
MEM. Cells were incubated with inoculum for 10 min at 4 °C and then 
for 50 min at 37 °C. Inoculum was removed and 3 ml of MEM containing 
0.9% agarose and of trypsin containing 1 mg ml−1 TPCK was overlaid onto 
the cell monolayer. Plates were then incubated at 37 °C for 72 h, and 
then plaques were counted after staining the cells with crystal violet.
Pulse oximetry
Mice were inoculated intranasally with 6,000 EID50 of influenza A 
virus (IAV) PR8 and arterial oxygen saturation was measured using the 
MouseOx system (STARR Life Sciences). Following infection, fur was 
removed around the neck of the mouse, and arterial oxygen saturation 
(SpO2) was measured using a throat collar sensor. After acclimatiza-
tion, oxygen saturation measurements were recorded for 3 min, and 
measurements were averaged over the measurement period.
Histology and morphometry viral-spread analysis
Lungs were dissected at 3 and 6 days after infection with 2,500 EID50 
of PR8. Lungs were inflated with 1 ml of 10% neutral-buffered forma-
lin, and then placed in a 15-ml conical tube containing a further 3 ml 
of formalin. Lungs were incubated in formalin at room temperature 
for at least 72 h to ensure complete fixation of the tissue. Lungs were 
embedded in paraffin blocks and then sectioned onto glass slides. Serial 
tissue sections were stained with haematoxylin and eosin for histol-
ogy. Immunohistochemical labelling of viral antigen was completed 
by using a primary goat polyclonal antibody (US Biological) against 
influenza A, USSR (H1N1) at 1:1,000 and a secondary biotinylated don-
key anti-goat antibody (sc-2042; Santa Cruz Biotechnology) at 1:200 
on tissue sections subjected to antigen retrieval for 30 min at 98 °C. 
The extent of virus spread was quantified by first capturing digital 
images of whole-lung sections stained for viral antigen using an Aperio 
ScanScope XT Slide Scanner (Aperio Technologies) and then manually 
outlining fields with the alveolar areas containing virus antigen-positive 
pneumocytes. The percentage of each lung field with infection/lesions 
was calculated using the Aperio ImageScope software. For histologic 
grading of lesions, a pathologist blinded to treatment group identity 
evaluated pulmonary lesions in haematoxylin and eosin-stained his-
tologic sections and assigned scores on the basis of their severity and 
extent as follows: 0, no lesions; 1, minimal, focal to multifocal, barely 
detectable; 15, mild, multifocal, small but conspicuous; 40, moderate, 
multifocal, prominent; 80, marked, multifocal coalescing, lobar; 100, 
severe, diffuse, with extensive disruption of normal architecture and 
function.
Assessment of IAV-infected cells by flow cytometry
Lungs were perfused with 10 ml cold 1× PBS injected into the right 
ventricle of the heart and then minced and digested in lung digestion 
buffer containing 400 U ml−1 collagenase I (Worthington Biochemical 
Corporation) and 50 U/ml of DNaseI (ThermoFisher) in HBSS for 30 min 
at 37 °C. Digested lungs were filtered through a 100-μm cell strainer 
and washed with HBSS. Red blood cell lysis was performed, and cells 
were washed and resuspended in FACS buffer. Cells were washed and 
then incubated with Trustain FcX anti-mouse CD16/CD32 (Fc Block) at a 
dilution of 1:100 for 10 min at room temperature. For surface staining, 
cells were then washed and incubated in 100 μl of FACS buffer (1% FBS, 
1 mM EDTA in 1× PBS) containing Ghost Dye Violet 510 (1:100), PE/Cy7 
anti-mouse CD45.2 (1:200), PacBlue anti-mouse CD11c (1:100), APC/
Cy7 anti-mouse CD11b (1:100), BV650 anti-mouse Gr-1 (1:200), APC 
anti-mouse CD326 (EpCAM) (1:100), PE anti-mouse CD90.2 (1:100), 
PerCP/Cy5.5 anti-mouse CD31 (1:100) for 30 min at room temperature. 
For intracellular staining, cells were fixed and membranes permeabi-
lized by incubating in 100 μl fixation–permeabilization solution (BD 
Biosciences) for 20 min on ice. Cells were washed with permeabilization 
buffer and then incubated with FITC anti-influenza A (1:100).
Assessment of CD8+ T cell responses
In order to assess immune cell populations by flow cytometry, whole 
lungs were dissected, minced, and incubated with spleen dissociation 
medium (STEMCELL) for 30 min at 37 °C. Red blood cell lysis was per-
formed, and cells were washed with HBSS and counted using a Vi-CELL 
XR cell counter (Beckman Coulter). For ex vivo stimulation and intracel-
lular cytokine staining, 1 × 106 total lung cells were plated in a 96-well 
plate for each condition. Cells were stimulated with Cell Stimulation 
Cocktail (Biolegend), containing PMA, ionomycin and brefeldin A, at a 
dilution of 1:500 or with influenza peptides at a concentration of 1 μM 
for 4 h. Following stimulation, cells were washed and then incubated 
with Trustain FcX anti-mouse CD16/CD32 (Fc Block) at a dilution of 
1:100 for 10 min at room temperature. For surface staining, cells were 
then washed and incubated in 100 μl FACS buffer (1% FBS, 1 mM EDTA 
in 1× PBS) containing Live/Dead Aqua (1:100), APC anti-mouse CD45.2 
(1:100), FITC anti-mouse CD3 (1:100), BV650 anti-mouse CD8 (1:200) 
and APC/Cy7 anti-mouse CD4 (1:200) for 30 min at room temperature. 
For intracellular staining, cells were fixed and membranes permeabi-
lized by incubating in 100 μl fixation–permeabilization solution (BD 
Biosciences) for 20 min on ice. Cells were washed with permeabiliza-
tion buffer and then incubated with PE/Cy7 anti-mouse IFNγ (1:100) 
for 30 min on ice.
For IAV peptide:MHC tetramer staining, 1 × 106 total lung cells were 
plated in a 96-well plate for each sample. Cells were incubated with 
APC PB1 (residues 703–711) tetramer (1:750), PE PA (residues 224–233) 
tetramer (1:750), and BV785 NP (residues 366–374) tetramer (1:250) 
for 1 h on ice. Then, cells were surface stained with FITC anti-mouse 
CD3 (1:100), BV650 anti-mouse CD8 (1:200), APC/Cy7 anti-mouse CD4 
(1:200) for 30 min on ice.
Lung tissue immunofluorescence
Lungs were dissected 9 days after infection with 2,500 EID50 of PR8. 
Lungs were inflated with 1 ml fixative containing 2% paraformaldehyde, 
0.1% Triton X-100 and 1% DMSO and then transferred to a 15 ml conical 
tube containing 3 ml of fixative for 24 h before cryoprotection with 
30% sucrose in PBS for an additional 24 h. Tissues were cryosectioned 
at 10 μm thickness and blocked in buffer comprised of PBS containing 
2% bovine serum albumin and 5% donkey serum. Tissues were stained 
overnight in blocking buffer containing 4 μg ml−1 rat anti-CD3 (Biole-
gend, clone 17A2) and 4 μg ml−1 rabbit anti-mouse versican GAG beta 
domain (Millipore Sigma, AB1033). Sections were washed in PBS before 
incubation with CF488-conjugated donkey anti-rat IgG (Biotium, 20027, 
lot 16C0301, 2 μg ml−1), CF568-conjugated donkey anti-rabbit IgG (Bio-
tium, 20098, lot 19C0110, 2 μg ml−1) and 10 μM DAPI for 1 h at room 
temperature. Slides were washed with PBS and mounted with Prolong 
Diamond Hardset Mounting Medium (ThermoFisher). High-resolution 
images were acquired using a Marianis spinning disk confocal micro-
scope (Intelligent Imaging Innovations) equipped with a 40× 1.3NA 
Plan-Neofluar objective, 405-nm, 488-nm and 561-nm laser lines and 
Prime 95B CMOS camera (Photometrics), and analysed using Slide-
book software (Intelligent Imaging Innovations). For quantification 
of CD3+ cells, 3–4 fields of view in the areas of tissue remodelling were 
collected for each lung.
Lung function test
For lung function studies, mice were infected with 2,500 EID50 of 
PR8. At 10 dpi, mice were anaesthetized with 2,2,2-tribromoethanol 
by intraperitoneal injection and a tracheal tube was inserted. Airway 
resistance and dynamic lung compliance were measured using the 
Buxco Finepointe Resistance and Compliance system (Data Sciences 
International). Data were collected using Buxco Finepointe software 
(Data Sciences International). Mice were mechanically ventilated at 
a rate of 140 breaths per minute. Five methacholine challenges were 
performed at doses of 1.5625, 3.125, 6.25, 12.5 and 25 mg ml−1, adminis-
tering the methacholine in 0.010 ml PBS. Following each methacholine 
challenge, resistance and compliance were measured for 3 min allow-
ing the mice to recover for 1 min after each measurement. Measure-
ments for resistance and compliance were averaged over the 3 min 
measurement period for each methacholine challenge and baseline 
measurements.
T cell migration assays
For migration assays, CD8+ T cells were isolated from spleens of 
C57BL/6J mice. To enrich for CD8+ T cells, samples were magnetically 
depleted using a cocktail of the following biotinylated antibodies: 
anti-mouse B220 (1:50), anti-mouse MHC class II (1:50), anti-mouse 
CD11b (1:100), anti-mouse CD49b (1:200), and anti-mouse CD4 (1:100). 
Up to 109 total spleen cells were incubated with the antibody cocktail for 
15 min on ice. Cells were washed with FACS buffer and then incubated 
with Miltenyi Streptavidin microbeads (1:25) for 15 min on ice. The 
cells were centrifuged at 500g for 5 min and then resuspended in 1 ml 
FACS buffer. The sample was added to a pre-equilibrated Miltenyi LS 
column and the flow-through enriched by CD8+ T cells was collected. 
CD8+ T cells were then activated with anti-mouse CD3e (1 μg ml−1) and 
anti-mouse CD28 (3 μg ml−1) antibodies in complete RPMI at 37 °C for 
72 h. Forty-eight hours before the migration assay, primary mouse 
lung fibroblasts, which were plated at a concentration of 105 cells per 
well in a 24-well plate the previous night, were stimulated with IL-1B 
(10 ng ml−1) and TNF (200 ng ml−1). For activation states (resting, DRFib, 
IRFib), sorted fibroblasts were plated at a density of 104 cells per well 48 h 
before the migration assay. 6.5 mm polycarbonate Transwell inserts 
with 8.0-μm pore size (Corning) were coated with 10 μg ml−1 versican 
purified from bovine aorta29 for 2 h at 37 °C. Versican was aspirated and 
Transwell inserts were transferred to the 24-well plate with stimulated 
fibroblasts. To test migration, 105 activated CD8+ T cells were added 
to the apical chamber of the Transwell in a volume of 100 μl complete 
DMEM. Cells were allowed to migrate to the basal chamber for 4 h at 
37 °C. After 4 h, supernatants from the basal chamber were collected 
and the number of lymphocytes were manually counted.
Quantification of proteins in mouse lung homogenates and 
bronchoalveolar lavage fluid
Cytokine levels in lung tissue homogenates were measured using LEG-
ENDplex cytokine bead arrays (Biolegend). Lungs were dissected from 
PR8-infected mice at 6 dpi and homogenized in 500 μl of PBS. Homog-
enized lung samples were centrifuged at 4,000 rpm for 10 min, and 
25 μl of undiluted supernatant was tested in the assay. The assay was 
performed according to the manufacturer’s instructions.
BAL washes were performed using 500 μl of PBS. Matrix protease 
levels in mouse BAL fluid were quantified using ELISA or a multiplexed, 
Luminex-based fluorescent assay. A custom Luminex kit (R&D Systems) 
was used to assay the following analytes: MMP-2, MMP-8, MMP-9, MMP-
12, TIMP-1 and TIMP-4. Duoset ELISA kits (R&D Systems) were used to 
assay the following analytes: ADAMTS4, MMP-3, MMP-13, and TIMP-3.
Human cohorts
For the PICFLU cohort, the study was approved by the lead site Bos-
ton Children’s Hospital (IRB X08-11-0534) and then at each enrolling 
site’s IRB (enrolling sites are listed in acknowledgements) and written 
informed consent was obtained from at least one parent or guardian. 
Patients were excluded before enrolment if they had an underlying 
condition predisposing them to severe influenza infection as has been 
described previously36,37. Additional cohort information is presented in 
Extended Data Fig. 10a. Endotracheal aspirate samples were obtained 
using standardized methods with 1.5 ml of sterile normal saline down 
the endotracheal tube then 3–4 breaths before obtaining the sample 
with 2 suctioning attempts aiming to collect at least 2 ml of aspirate. The 
sample was put on ice and transferred immediately to the laboratory for 
processing. One aliquot was immediately frozen (−80 °C) and the rest 
was centrifuged. The supernatant was aliquoted and frozen at −80 °C.
For the Guangzhou cohort, the study was approved by the ethics com-
mittee of the First Affiliated Hospital of Guangzhou Medical University 
(no: 2016-78), and informed consent was obtained from all patients or 
their guardians. Additional cohort information is presented in Extended 
Data Fig. 10c.
For the Taiwan cohort, the human participants’ protocol was reviewed 
and approved by the Johns Hopkins School of Medicine and the Chang 
Gung Memorial Hospital Institutional Review Boards (IRB00091667). 
Informed consent was obtained from all patients or their guardians. 
This protocol allowed for the collection of residual BAL and sputum 
samples that were initially collected for clinical purposes from patients 
with influenza (Extended Data Fig. 10c).
For lung samples from de-identified, deceased donors, the tis-
sues used were procured by the NDRI with support from NIH grant 
U42OD11158. All NDRI consent forms and protocols were reviewed 
and approved by the Institutional Review Board at the University of 
Pennsylvania. Research involving these tissues was determined to not 
involve human participants by the Institutional Review Board at St Jude 
Children’s Research Hospital.
Quantification of matrix protease and cytokine/chemokine 
protein levels in human samples
Cytokine and chemokine levels were measured using Milliplex Human 
Cytokine/Chemokine Magnetic Bead Panel—Premixed 41 plex. MMP 
and TIMP protein levels were quantified using the following Milliplex 
bead-based multiplexed assay: Human MMP Magnetic Bead Panel 1 
(MMP-3, MMP-12, MMP-13), Human MMP Magnetic Bead Panel 2 (MMP-1, 
MMP-2, MMP-7, MMP-9, MMP-10) and Human TIMP Magnetic Bead 
Panel 2 (TIMP-1, TIMP-2, TIMP-3, TIMP-4). ADAMTS4 and ADAMTS5 
were measured using Duoset ELISA kits (R&D Systems).
Cytokine correlation matrices
Correlation matrices were generated using samples analysed in sever-
ity analyses, with log10-transformed cytokine levels. To control for 
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potential effects of age and day of sample collection (days after symp-
tom onset), we computed partial pairwise Spearman correlations and 
assessed their statistical significance using the R psych package (https://
cran.r-project.org/web/packages/psych/index.html). Correlations 
were visualized using the R corrplot package (https://github.com/cran/
corrplot/blob/master/R/corrplot.R), and correlations with P < 0.05 
after FDR adjustment were excluded.
Severity analyses
For analysis of association of ADAMTS4 levels with severity of infec-
tion in the PICFlu cohort, we used three distinct indicators of sever-
ity: PrMODS or death, PrAHRF or death, and VFDs less than 10. In 
survivors, ‘prolonged’ was defined as being present on or after day 7 
of admission to paediatric intensive care or being on extracorporeal 
membrane oxygenation on or after day 7. PrAHRF was defined as partial 
pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less 
than 200 and mechanical ventilator support, which are criteria for 
moderate-severe ARDS1. VFDs were defined as days alive and free of 
invasive or non-invasive mechanical ventilation up to 28 days38. Owing 
to the bimodal distribution of VFDs, we used a cut-off of 10 VFDs to clas-
sify cases as severe (Extended Data Fig. 10b) ADAMTS4 was modelled 
as a predictor of these categorical outcomes using logistic regressions 
in R that explicitly included gender, age, baseline health (‘previously 
healthy’), and steroid administration. FDR adjustments for multiple 
testing were applied independently to each model. Patients were con-
sidered ‘previously healthy’ if they were, upon admission, otherwise 
healthy, on no prescription medications, without underlying medical 
conditions, and not dependent on any medical devices before initial 
admission to the hospital for flu. No violations of the model assump-
tions were found in any reported results after specifically checking for: 
(1) the assumption that the relationship between continuous predictor 
variables and the logit of the outcome is linear, (2) evidence of extreme 
values in continuous predictors (as indicated by standard residuals 
with an absolute value over three), and (3) evidence of multicollinearity 
among variables (as indicated by variance inflation factors (VIFs)). Odds 
ratios were visualized using the sjPlot package in R (https://strengejacke. 
github.io/sjPlot/).
Sequence data used for analyses
Hallmark gene sets from the Molecular Signatures Database were used 
for GSEA (https://www.gsea-msigdb.org/gsea/msigdb/index.jsp). The 
following publicly available datasets were used for meta-analysis: http:// 
shaleklab.com/wp-content/uploads/2018/08/20180822_PolypAll_cleaned_ 
rawdata.txt.zip; http://shaleklab.com/wp-content/uploads/2018/ 
06/20180822_PolypAll_cleaned_metadata.txt; https://browser.immport. 
org/browser?path=SDY998%2FResultFiles%2FRNA_sequencing_result, 
GSE145926_RAW.tar (https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE145926); GSE135893_barcodes.tsv.gz, GSE135893_genes.
tsv.gz, and GSE135893_IPF_metadata.csv.gz (https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE135893); GSE130148_raw_counts.
csv.gz and GSE130148_barcodes_cell_types.txt.gz (https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE130148); GSE122960_RAW.tar 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122960); 
GSE128169_RAW.tar (https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE128169); and GSE132771_RAW.tar (https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE132771).
Statistical analyses
For experiments involving mice, statistical analyses were performed 
using Graphpad Prism v.7.0d software. For analysis of human samples, 
statistical analyses were performed in R statistical software v.3.5.0 and 
as detailed in the sections above.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
Cohort cytokine and ADAMTS4 data are available in Supplementary 
Tables 3, 4. Single-cell and spatial gene-expression data are available 
on the NCBI Short Read Archive under BioProjects PRJNA612345 and 
PRJNA613670. Source data are provided with this paper.
Code availability
All analyses were conducted using publicly available software as 
detailed in the methods. All code is available upon request.
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Extended Data Fig. 1 | Single-cell gene-expression profiling of CD45− lung 
cells during severe influenza virus infection in mice. a, Cell hashing of 
biological replicates for each time point. t-SNE of CD45- cells from mouse lungs 
at all time points. Cells from individual mice (n = 5 for time points 0, 1, and 3 dpi, 
and n = 4 for 6 dpi) were labelled with DNA-tagged antibodies (JCChto 10, 11, 12, 
13, and 14) and pooled within time points. Pooled cells for each time point were 
run on separate 10x Genomics gel bead reactions. Cells are colour-coded 
according to hashtag oligo ID as indicated at the right of the graph. ‘Unknown’ 
(purple) indicates that an insufficient number of hashtags were sequenced in 
order to determine the ID. Cells are also symbol-coded according to time point 
after infection: 0 dpi (circle), 1 dpi (triangle), 3 dpi (square), 6 dpi (cross).  
b, Feature plots of signature genes used to identify mouse lung cell 
populations. The following genes were used to identify general populations of 
cells: immune cells (Ptprc), epithelial cells (Epcam), endothelial cells (Pecam1, 
Lyve1, Vwf ), and mesenchymal cells (Col1a2). The following genes were used to 
identify specific cell populations within the main types of cells: T cells (Cd3e),  
B cells (Cd19), myeloid cells (Fcgr1), neutrophils (Mmp9), type I pneumocytes 
(Akap5), type II pneumocytes (Sftpc), ciliated epithelial cells (Foxj1), club cells 
(Scgb1a1), lymphatic endothelial cells (Pecam1, Thy1), fibroblasts (Pdg fra), 
pericytes and smooth muscle cells (Acta2), mesothelial cells (Msln), and 
platelets (Pf4). c, Violin plot of expression of influenza A PR8 transcripts by 
scGEX in non-immune lung cells. d, Overlay of days post-infection on t-SNE 
clustering of mouse lung cells.
Extended Data Fig. 2 | See next page for caption.
Article
Extended Data Fig. 2 | Summary of gene-set enrichment analysis of mouse 
and human fibroblast populations. a, Relative expression of the indicated 
gene sets in individual mouse fibroblasts and smooth muscle cells. Gene sets 
representing ECM structural proteins (EXTRACELLULAR_MATRIX1 and 
COLLAGEN1) inflammatory cytokine responses (HALLMARK_IL6_STAT3_
SIGNALING1, GO_REGULATION_OF_TYPE_I_INTERFERON_MEDIATED_
SIGNALING_PATHWAY, HINATA_NFKB_IMMU_INF1), and myogenesis 
(HALLMARK_TGF_BETA_SIGNALING1, HALLMARK_MYOGENESIS1) are plotted. 
b, Pairwise comparison of selected hallmark gene sets between mouse 
inflammatory fibroblast clusters 4 (DRFibs) and 6 (IRFibs). Each bar represents 
the normalized enrichment score (NES) from GSEA comparing all cells in 
cluster 4 (n = 892 cells) and cluster 6 (n = 749 cells). c, t-SNE clustering of human 
COL1A2 expressing mesenchymal cells from five human lung biopsy samples. 
Relative expression of the indicated gene sets in individual human fibroblasts 
and smooth muscle cells. Gene sets representing ECM structural proteins 
(EXTRACELLULAR_MATRIX1 and COLLAGEN1) inflammatory cytokine 
responses (HALLMARK_IL6_STAT3_SIGNALING1,HALLMARK_INTERFERON_
ALPHA_RESPONSE1, HINATA_NFKB_IMMU_INF1), and myogenesis 
(HALLMARK_TGF_BETA_SIGNALING1, HALLMARK_MYOGENESIS1) are plotted. 
d, Dot plots of key genes related to cytokine/chemokine induction and ECM-
production and modification in human lung mesenchymal cells.
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Extended Data Fig. 3 | See next page for caption.
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Extended Data Fig. 3 | Validation of inflammatory fibroblasts 
transcriptional states by flow cytometry. a, b, Feature plots of Itga5/ITGA5 
and Cd9/CD9 in mouse and human mesenchymal cells expressing Col1a2/
COL1A2 from scGEX data. Legend indicates relative expression within each 
dataset. c, Gating strategy for identifying inflammatory fibroblast 
transcriptional states based on ITGA5 (CD49e) and CD9 staining. d, Total cell 
number for IRFibs (blue) and DRFibs (green) in the lungs during IAV infection. 
e, Gene expression in sorted ITGA5hiCD9lo, ITGA5lo CD9hi, and bulk CD45- cells 
as measured by qPCR. Each data point represents an independent biological 
replicate (CD45-, n = 5; ITGA5hiCD9lo, n = 4, ITGA5lo CD9hi, n = 4). Error bars 
represent standard error of the mean. f, Principal component analysis of sorted 
fibroblast populations and bulk CD45- cells from mouse lungs. g, In vitro 
stimulation of mouse lung fibroblasts with IL-1/TNF. Representative flow plots 
of ITGA5 staining before and after stimulation. Charts at bottom indicate 
percentage of ITGA5hi fibroblasts (P = 2 × 10−6)) and median fluorescence 
intensity (MFI) for ITGA5 (P = 0.002). Each data point represents an 
independent biological replicate (unstim, n = 3; IL1/TNF, n = 3). For statistical 
analysis, groups were compared using a two-sided Student’s t-test.
Extended Data Fig. 4 | Assessment of fibroblast cell surface phenotype in 
human lung samples. a, Gating strategy for identifying live, CD45−EpCAM− 
CD31−PDGFRA+ cells in human lung samples. b, Each flow plot represents cells 
gated on live, CD45−EpCAM−CD31−PDGFRA+ from an individual sample as 
indicated in the gating strategy. Resting fibroblasts (ITGA5loCD9hi) and 
damage-responsive fibroblasts (ITGA5hiCD9lo) are labelled on representative 
flow plots.
Article
Extended Data Fig. 5 | See next page for caption.
Extended Data Fig. 5 | Regulation of ECM-related gene expression in human 
and mouse respiratory cells following cytokine stimulation. a, Heat map 
representing ∆Ct values (normalized to ACTB) in NHBFs and normal human 
bronchial epithelial cells (NHBEs) stimulated for 24 h with the indicated 
cytokines or viruses, and nasal wash cells (NWCs). Green shading highlights 
stimulation with IL-1 cytokines, while blue shading indicates stimulation with 
indicated viruses. ECM-related genes are grouped by unsupervised, 
hierarchical clustering. b, Heat map representing log2-transformed fold-
change in differentiation normal human bronchial epithelial cells (NHBEs) 
stimulated with the indicated cytokines/viruses. Values are relative to 
untreated NHBEs. c, Heat map representing log2-transformed fold-change in 
gene expression relative to untreated cells as determined by the ∆∆Ct method. 
Matrix protease genes ( y-axis) and treated cell samples (x-axis) were grouped 
by unsupervised, hierarchical clustering. d, Assessment of ECM protease and 
TIMP protein levels in bronchoalveolar lavage fluid collected from mice.  
Heat maps of log2-transformed fold-change values relative to mock-
infectedmice for each of the indicated analytes over the course of IAV infection. 
Protein levels in the BAL (top) are compared to log2-transformed fold-change 
values relative to mock-infected mice for gene expression as measured by qPCR 
in whole lung homogenates. The kinetics for individual analytes plotting 
absolute protein concentrations are presented at the right (0 dpi, n = 5 mice; 
3 dpi, n = 5; 6 dpi, n = 5; 9 dpi, n = 5; 12 dpi, n = 4; 21 dpi, n = 5). Error bars represent 
s.e.m.
Article
Extended Data Fig. 6 | Meta-analysis of publicly available human disease 
single-cell gene-expression datasets. a, Table of datasets from eight distinct 
studies (seven from respiratory disease and one from rheumatoid arthritis), 
which were aggregated for meta-analysis. Cells expressing at least one 
transcript of ADAMTS4 were identified. b, c, Uniform manifold approximation 
and projection (UMAP) clustering of ADAMTS4+ cells with overlay of study or of 
unsupervised clustering by cell type. d, Volcano plot of differentially expressed 
genes in cluster 14. Differentially expressed genes are based on comparison to 
all cells in the dataset. Each data point represents a gene and is colour-coded 
according to whether the gene was above a threshold for adjusted P value 
(<10−3, blue), log2-transformed fold-change (>|2|, green), adjusted P value and 
log2-transformed fold-change (red), or not significant (grey). e, Expression 
level of ADAMTS4 in the pulmonary fibrosis dataset from Habermann et al.12 by 
disease state. f, Expression level of ADAMTS4 in the Habermann et al.12 dataset 
by cell type (endothelial, epithelial, immune, mesenchymal) and disease state.
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Extended Data Fig. 7 | Spatial transcriptomics of lung sections from mice 
collected 10 days after infection. a, H&E staining (left) and unsupervised 
clustering analysis (right) are presented for four lung sections from four 
individual mice, representing four biologically independent samples. Similar 
results were obtained across the four independent samples. ‘Ident’ indicates 
the identity of each lung region determined by unsupervised clustering of 
transcriptional profiles. b, Relative gene expression of key fibroblast-
associated genes (Itga5, Lox, Cd9, Timp3) in a representative lung section.  
c, Summary of Gene Ontology (GO) analysis of lung regions (clusters) 
determined by unsupervised clustering. The chart indicates the lung region 
(‘Cluster’), the GO pathway (‘GO’), fold enrichment of the indicated pathway in 
the indicated region (‘Fold Enrichment’), and the P value using false discovery 
rate to assess statistical significance (‘FDR’). d, Average log fold change in 
expression among all spots pertaining to lung regions (n = 4 independent lung 
sections from four individual mice). Enrichment determined using two-sided 
Wilcoxon rank sum test with FDR adjustment. Asterisk (*) indicates that 
adjusted P < 0.00001 (exact P values in Source Data).
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Extended Data Fig. 8 | Assessment of IAV infection in Adamts4+/+ and 
Adamts4−/− mice. a, Weight loss curves of Adamts4+/+ and KO mice following 
lethal IAV challenge with 6,000 EID50 PR8. Data points represent mean ± s.d. 
(WT, n = 27; KO, n = 16). Data are pooled from 5 independent experiments.  
b, Viral plaque titres in BAL fluid and lung tissue homogenates at 6 dpi. Each 
data point represents a biologically independent mouse (BAL: WT, n = 12; KO, 
n = 11; lung tissue: WT, n = 5; KO, n = 5). Groups were compared using a two-sided 
Mann–Whitney U test. Error bars represent s.e.m. c, Cell-type specific infection 
based on IAV nucleoprotein (NP) positivity as assessed by flow cytometry and 
gating strategy for identifying populations for cell-type specific infection. 
Populations were identified using the following markers: Epithelial (CD45− 
EpCAM+), Endothelial (CD45−CD31+), Fibroblasts (CD45−EpCAM−CD90+), 
Monocytes (CD45+CD11c−CD11b+Gr-1lo), Neutrophils (CD45+CD11c−CD11b+Gr-1hi). 
Each data point represents a biologically independent mouse (uninfected, 
n = 2; WT, n = 7; KO, n = 7). Groups were compared using a two-sided Mann–
Whitney U test. Error bars represent s.e.m. d, Total protein concentration in 
BAL fluid as measured by BCA assay at 6 dpi. Each data point represents a 
biologically independent mouse (uninfected, n = 8; WT, n = 7; KO, n = 5). Groups 
were compared using a two-sided Mann–Whitney U test. Error bars represent 
s.e.m. e, Cytokine concentrations in BAL fluid at 6 dpi as measured by 
multiplexed cytokine bead arrays (WT, n = 8; Adamts4−/−, n = 8). f, Measurement 
of dynamic lung compliance at 10 days after infection following sublethal 
challenge with IAV (Uninfected: WT, n = 8; KO = 3, Infected: WT n = 8, KO, n = 9). 
Error bars represent s.e.m. For statistical analysis, groups were compared 
using a two-sided Mann–Whitney U test.
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Extended Data Fig. 9 | Versican accumulates in the lung during severe IAV 
infection in mice and affects localization and responses of T cells.  
a, Representative fluorescence microscopy images of VCAN staining at 0, 3, 
and 6 days after infection from two independent experiments. Scale bar, 200 μm.  
Quantification of VCAN staining is presented at the right. Area-under-curve 
was determined from the average of five intensity profiles of fluorescence per 
image. Each data point represents average of intensity profiles for each 
individual mouse (0 dpi, n = 6, 3 dpi, n = 8; 6 dpi, n = 6). Error bars represent 
s.e.m. b, Representative images of intact VCAN staining in lung sections from 
Adamts4+/+ and Adamts4−/− collect 9 days after infection from two independent 
experiments. Note that images are also presented in Fig. 3h with CD3 staining. 
Scale bar, 50 μm. c, Heat map representing log2-transformed fold change 
values in gene expression for each genotype relative to mock-infected controls. 
Whole lungs were collected 9 days after infection. d, Gating strategy for 
identifying CD8+ T cells in lungs of IAV-infected mice. CD8+ T cells were 
identified as CD45+CD3+CD8+. e, Frequency of IFNγ+ in ADAMTS4 WT and KO 
mice at 9 and 12 days after infection. Each data point represents a biologically 
independent animal (9 dpi: WT, n = 5; KO, n = 5; 12 dpi: WT, n = 5; KO, n = 4). f, Total 
cell number of tetramer+ CD8+ T cells in the lung at 9 days after infection  
(WT, n = 10; KO, n = 10). Error bars represent s.e.m.
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Female 31 (36.9)
Hispanic Ethnicity 19 (22.6)
Race
White 63 (75.0)
Black 14 (16.7)
Mixed/Other 7 (8.3)
Age, years, median (IQR) 7.3 (2.8, 11.4)
Baseline Health Status
Previously Healthy 54 (64.3)
Mild Asthma no controllers 16 (19.0)
Other Underlying Respiratory Disorder 3 (3.6)
Other Underlying Condition(s) 12 (14.3)
Influenza Type
Influenza A 65 (77.4)
Influenza A(H1N1)pdm09 37 (44.0)
Influenza A H3N2 25 (29.8)
Influenza A Seasonal H1 2 (2.4)
Influenza A no subtype 1 (1.2)
Influenza B 18 (21.4)
Influenza A(H1N1)pdm09/Influenza B 1 (1.2)
Other Virus Co-detected 17 (20.2)
Bacterial Co-Infection Suspected or Confirmed 45 (53.6)
Secondary Complications
Extracorporeal Life Support 17 (20.2)
Acute Respiratory Distress Syndrome 48 (57.1)
Shock Requiring Vasopressors (CV SOFA > 3) 45 (53.6)
Illness Severity & Outcomes
PRISM III Score, median (IQR) 8.0 (3.0, 15.5)
Duration Mechanical Ventilation, hours, median (IQR) 137.4 (66.8, 273.8)
Duration PICU stay, hours, median (IQR) 184.0 (106.0, 338.5)
Hospital Mortality 7 (8.3)
Ventilator Free Days, median (IQR) 22.2 (14.9, 25.2)
Prolonged MODS or Death 20 (23.8)
Prolonged Acute Hypoxic Respiratory Failure or Death 22 (26.2)
PRISM = Pediatric Risk of Mortality Score; PICU = Pediatric Intensive Care Unit; CV SOFA = 
Cardiovascular Sequential Organ Failure Assessment Score; Ventilator Free Days: days alive 
and free of invasive or non-invasive mechanical ventilation up to 28 days; MODS = Multiple 
Organ Dysfunction Syndrome; Prolonged MODS (PrMODS): MODS and/or ECMO on/after day 7; 
Prolonged Acute Hypoxic Respiratory Failure (PrAHRF): PaO2/FiO2 < 200 and invasive 
mechanical ventilation and/or ECMO on/after day 7
Guangzhou    
N = 30
Taiwan         
N = 37
Female 9 (30) 15 (41)
Race
Asian 30 (100) 37 (100)
Age, years, median (IQR) 56 (39.5, 67.0) 61.9 (41.5, 75.7)
Influenza Type
Influenza A 30 (100) 32 (86.4)
Influenza A H1N1 14 (46.7) 21 (56.8)
Influenza A H3N2 0 (0) 11 (29.7)
Influenza A H7N9 16 (53.3) 0 (0)
Influenza B 0 (0) 5 (13.5)
Bacterial Co-Infection Suspected or Confirmed 24 (80.0) NA
Illness Severity & Outcomes
Hospital Mortality 5 (16.7) 4 (10.8)
Ventilator Free Days, median (IQR) 0 (0, 8.8) 20 (0, 24.5) 
Ventilator Free Days: days alive and free of invasive or non-invasive mechanical 
ventilation up to 28 days;
PRMODSorDeath
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Extended Data Fig. 10 | Association of ADAMTS4 with clinical measures 
from three independent human cohorts. a, Demographic information for the 
Paediatric Intensive Care Influenza (PICFLU) cohort. b, Histogram of VFDS for 
the PICFlu cohort. c, Odds ratios for PRMODS and PRAHRF, as well as gender, 
previously healthy, age, and steroids as covariates. d, Demographic 
information for influenza infection cohorts in Taiwan and Guangzhou.  
e, Compartmentalization of ADAMTS-4 in samples from upper (nasal wash) and 
lower (sputum, BALF, ETA) respiratory tracts (NW, n = 131; sputum, n = 48; BALF, 
n = 25; ETA, n = 34). Box plots were generated for samples in which ADAMTS4 
protein was detectable. Center line indicates median, bottom and top of boxes 
indicate first and third quartiles, and whiskers extend to 1.5 times the 
interquartile range. f, Odds ratios for VFDS <10, including gender and age as 
covariates, in combined analysis of three human cohorts. Odds ratios (c, f) 
determined using logistic regression with FDR adjustments for multiple 
testing.
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Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency 
in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection High-throughput qPCR using Fluidigm Biomark - Fluidigm Biomark Collection Software Version 4.5.2 
Histology and viral spread analysis - Aperio ImageScope software Version 12.3.3 
Flow Cytometry - BD FACSDIVA Software Version 8.0.1 
Immunofluorescence - Slidebook Software, Intelligent Imaging Innovations Version 6.0.19 
Lung Resistance/Compliance - Buxco Finepointe Software Version 2.6 
Multiplexed Cytokine Assays - Luminex xponent Version 3.1 
 
Data analysis 10x Genomics Single Cell Gene Expression - Data processing: CellRanger v3.0.2 (10x Genomics), Data analysis: Seurat v3.0.0.900 
Spatial Transcriptomics - Data processing: SpaceRanger v1.0.0 (10x Genomics), Data analysis: Seurat v3.1.4.9901 
Cytokine Correlation Matrices - R psych package v1.9.11, R corrplot package v0.84 
Severity Analyses - sjPlot package v2.8.2 
Flow Cytometry - FlowJo 10.4.2 
R packages were run using R statistical software, version 3.5.0 "Joy in Playing" 
Statistical tests on data from mouse experiments was performed in Graphpad Prism 7.0d 
 
All analyses were conducted using publicly available software as detailed in the methods. All code is available upon request. 
 
 
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
Cohort cytokine and ADAMTS4 data can be found in Supplemental Tables 6 and 7. Single-cell gene expression data and spatial gene expression data are available on 
the NCBI Short Read Archive under BioProjects PRJNA612345 and PRJNA613670. Hallmark gene sets from the Molecular Signatures Database were used for gene 
set enrichment analysis (https://www.gsea-msigdb.org/gsea/msigdb/index.jsp). The following publicly available datasets were used for meta-analysis: 
20180822_PolypAll_cleaned_rawdata.txt.zip (http://shaleklab.com/wp-content/uploads/2018/08/20180822_PolypAll_cleaned_rawdata.txt.zip) and 
20180822_PolypAll_cleaned_metadata.txt (http://shaleklab.com/wp-content/uploads/2018/06/20180822_PolypAll_cleaned_metadata.txt); 
celseq_matrix_ru1_molecules.tsv.725583.gz and celseq_meta_unfiltered.tsv.725587.gz (https://browser.immport.org/browser?path=SDY998%2FResultFiles%
2FRNA_sequencing_result); GSE145926_RAW.tar (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE145926), GSE135893_barcodes.tsv.gz, 
GSE135893_genes.tsv.gz, and GSE135893_IPF_metadata.csv.gz (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE135893); GSE130148_raw_counts.csv.gz 
and GSE130148_barcodes_cell_types.txt.gz (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130148); GSE122960_RAW.tar (https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122960); GSE128169_RAW.tar (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128169); 
GSE132771_RAW.tar (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132771).  
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For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size For experiments involving mice, sample sizes were determined empirically based on previous studies involving similar experiments. Sample 
sizes are indicated in the figure legends for each experiment. For studies involving human samples, sample sizes were not calculated due to 
the limited availability of samples. All available samples with excess sample and corresponding cytokine data were tested.
Data exclusions No data were excluded from the analyses.
Replication All experiments were replicated as indicated in the manuscript with at least two independent experiments. All attempts to replicate findings 
were successful.
Randomization For experiments involving mice, animals were age and sex matched. For experiments involving human samples, samples were not randomized 
as there was no intervention based on group. Covariates, including age, gender, baseline health status, and corticosteroid administration, 
were controlled for as indicated in the methods section. 
Blinding For survival experiments in mice requiring euthanasia, investigators were blinded to identity of the animals. For histology, the pathologist was 
blinded to the genotype of the animals. For other non-survival experiments, mice were allocated to groups based on genotype and 
subsequently identified by ear tag number to reduce potential bias during collection of objective measurements. For experiments involving 
human samples, investigators collecting the data were blinded to patient group.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems
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Methods
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Antibodies
Antibodies used Trustain FcX anti-mouse CD16/32 antibody - 93, Biolegend, Cat: 101320, Lot: P0161031218704 
Human Trustain FcX - Biolegend, Cat: 422302 
Ghost Dye Violet 510 - TONBO, Cat: 13-0870,Lot: D0870082117133 
APC anti-mouse CD45.2 antibody - Mouse IgG2a, 104, Biolegend, Cat: 109814  
PE anti-mouse H-2 antibody - Rat IgG2a, M1/42, Biolegend,  Cat: 125506, Lot: B236343 
PE anti-human CD45 - Mouse IgG1, HI30, iCyt, Lot: 41152 
PE anti-human beta2-microglobulin - Mouse IgM, TU99, BD Pharmigen, Cat: 551337, Lot: 43471 
FITC anti-influenza A antibody - Mouse IgG2a, A1, Millipore, Cat: MAB8257F, Lot:2730954 
PE/Cy7 anti-mouse CD45.2  - Mouse IgG2a, 104, Biolegend, Cat: 109830, Lot: B228756 
PE anti-mouse CD90.2 - Rat IgG2a, 53-2.1, Biolegend, Cat: 140308, Lot: B204073 
PerCP Cy5.5 anti-mouse CD31 - Rat IgG2a, 390, Biolegend, Cat: 102420, B247172 
PacBlue anti-mouse CD11c - Armenian Hamster IgG, N418, Biolegend, Cat: 117322, Lot: B213515 
APC/Cy7 anti-mouse CD11b - Rat IgG2b, M1/70, TONBO, Cat: 25-0112, Lot: C0112112916253 
BV650 anti-mouse Gr-1 - Rat IgG2b, RB6-8C5, Biolegend, Cat: 108442, Lot: B234643 
APC anti-mouse CD326 (EpCAM) - Rat IgG2a, G8.8, Biolegend, Cat:118214, Lot: B217174 
PE/Cy7 anti-mouse IFNg - Rat IgG1, XMG1.2, BD Pharmigen, Cat: 561040, Lot: 7202642 
FITC anti-mouse CD3 - Rat IgG2b, 17A2, Biolegend, Cat: 100204, Lot:E16592-103 
BV650 anti-mouse CD8a - Rat IgG2a, 53-6.7, Biolegend, Cat: 100742, Lot: B212054 
APC/Cy7 anti-mouse CD4 - Rat IgG2b, GK1.5, Biolegend, Cat: 100414, Lot: B180930 
Anti-mouse CD3 - Rat IgG2b, 17A2, Biolegend, Cat: 100202, Lot: B248471 
Anti-mouse versican GAG beta domain - Rabbit, Polyclonal, Millipore Sigma, Cat: AB1033, Lot: 2960529 
Anti-influenza A, USSR (H1N1) - Donkey, Polyclonal, US Biological, Cat: I7650-80B 
BV605 anti-mouse CD45 - Rat IgG2b, 30-F11, Biolegend, Cat: 103155, Lot: B278000 
BV421 anti-mouse CD326 (EpCAM) - Rat IgG2b, G8.8, Biolegend, Cat: 118225, Lot: B265073 
FITC anti-mouse CD317 (BST2) - Rat IgG2b, 927, Biolegend, Cat: 127008, Lot: B292371 
PE anti-mouse CD9 - Rat IgG2a, MZ3, Biolegend, Cat: 124806, Lot: B253483 
APC anti-mouse CD49e (ITGA5) - Rat IgG2a, 5H10-27(MFR5), Biolegend, Cat: 103814, Lot: B264927 
APC anti-human CD45 - Mouse IgG1, 2D1, Biolegend, Cat: 368512, Lot: B237418 
Secondary biotinylated anti-goat IgG, Donkey polyclonal, Santa Cruz, Cat: sc-2042 
CF488 anti-rat IgG, Donkey polyclonal, Biotium, Cat: 20027, Lot: 16C0301 
CF568 anti-rabbit IgG, Donkey polyclonal, Biotium, Cat: 20098, Lot: 19C0110 
Biotin anti-mouse B220 - Rat IgG2a, RA3-6B2, Biolegend, Cat: 103204, Lot: B268525 
Biotin anti-mouse MHC II (I-A/I-E) - Rat IgG2b, M5/114.15.2, Biolegend, Cat: 107604, Lot: B235112 
Biotin anti-mouse CD4, Rat IgG2b, GK1.5, Biolegend, Cat: 100404, Lot: B191781 
Biotin anti-mouse CD49b - Rat IgM, DX5, Biolegend, Cat: 108904, Lot: B215293 
Biotin anti-mouse CD11b - Rat IgG2b, M1/70, Biolegend, Cat: 101204, Lot: B241116 
Anti-mouse CD3e - Armenian Hamster IgG, 145-2C11, Biolegend, Cat: 100302, Lot: B211546 
Anti-mouse CD28 - Syrian Hamster IgG, 37.51, eBioscience, Cat: 14-0281-86, Lot: E03644-1632 
BV605 anti-human CD45 - Mouse IgG1, HI30, Biolegend, Cat: 304042, Lot: B242281 
BV785 anti-human CD326 (EpCAM) - Mouse IgG2b, 9C4, Biolegend, Cat: 324237, Lot: B262589 
APC Fire 750 anti-human CD31 - Mouse IgG1, WM59, Biolegend, Cat: 303142, Lot: B292519 
PE/Cy7 anti-human CD140a (PDGFRA) - Mouse IgG1, 16A1, Biolegend, Cat: 323508, Lot: B250541 
APC anti-human CD49e (ITGA5) - Mouse IgG2b, NKI-SAM-1, Biolegend, Cat: 328012, Lot: B243442 
PE anti-human CD9 - Mouse IgG1, HI9a, Biolegend, Cat: 312106, Lot: B297661 
Validation Trustain FcX anti-mouse CD16/32 - validated for flow cytometry by staining mouse lung cells according to vendor's website. 
Human Trustain FcX - validated for flow cytometry by staining human lung cells according to vendor's website. 
Ghost Dye Violet 510 - validated for flow cytometry by staining mouse splenocytes. Flow plot shown on vendor's website. 
APC anti-mouse CD45.2 - validated for flow cytometry by staining mouse splenocytes. Flow plot shown on vendor's website. 
PE anti-mouse H-2 - validated for flow cytometry by staining mouse splenocytes. Flow plot shown on vendor's website. 
PE anti-human CD45 -  validated for flow cytometry by staining human PBMCs. Flow plot shown on vendor's website. 
PE anti-human beta2-microglobulin - validated for flow cytometry by staining human PBMCs. Flow plot shown on vendor's 
website. 
FITC anti-influenza A antibody - validated for flow cytometry by staining mouse lung cells according to vendor's website. 
PE/Cy7 anti-mouse CD45.2  - validated for flow cytometry by staining mouse splenocytes. Flow plot shown on vendor's website. 
PE anti-mouse CD90.2 - validated for flow cytometry by staining mouse splenocytes. Flow plot shown on vendor's website. 
PerCP Cy5.5 anti-mouse CD31 -  validated for flow cytometry by staining mouse splenocytes. Flow plot shown on vendor's 
website. 
PacBlue anti-mouse CD11c - validated for flow cytometry by staining mouse splenocytes. Flow plot shown on vendor's website. 
APC/Cy7 anti-mouse CD11b - validated for flow cytometry by staining mouse bone marrow cells. Flow plot shown on vendor's 
website. 
BV650 anti-mouse Gr-1 - validated for flow cytometry by staining mouse bone marrow cells. Flow plot shown on vendor's 
website. 
APC anti-mouse CD326 (EpCAM) -  validated for flow cytometry by staining TE-71 cells (mouse thymic epithelial stromal cell line). 
Flow plot shown on vendor's website. 
PE/Cy7 anti-mouse IFNg - validated for flow cytometry by staining mouse splenocytes. Flow plot shown on vendor's website. 
FITC anti-mouse CD3 - validated for flow cytometry by staining mouse splenocytes. Flow plot shown on vendor's website. 
BV650 anti-mouse CD8a - validated for flow cytometry by staining mouse splenocytes. Flow plot shown on vendor's website. 
APC/Cy7 anti-mouse CD4 - validated for flow cytometry by staining mouse splenocytes. Flow plot shown on vendor's website. 
Anti-mouse CD3 - validated for immunohistochemistry by staining mouse spleen sections. Sections shown on vendor's website. 
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Anti-mouse versican GAG beta domain - validated for immunohistochemistry by staining mouse neural tube and limb bud. 
Sections shown on vendor's website. 
Anti-influenza A, USSR (H1N1) - validated for immunohistochemistry by staining uninfected and infected mouse lung sections 
according to vendor's website. 
BV605 anti-mouse CD45 - validated for flow cytometry by staining mouse splenocytes. Flow plot shown on vendor's website 
BV421 anti-mouse CD326/EpCAM - validated for flow cytometry by staining TE-71 cells (mouse thymic epithelial stromal cell 
line). Flow plot shown on vendor's website. 
FITC anti-mouse CD317 (BST2) - validated for flow cytometry by staining mouse splenocytes. Flow plot shown on vendor's 
website. 
PE anti-mouse CD9 - validated for flow cytometry by staining mouse bone marrow cells. Flow plot shown on vendor's website. 
APC anti-mouse CD49e (ITGA5) - validated for flow cytometry by staining mouse bone marrow cells. Flow plot shown on vendor's 
website. 
APC anti-human CD45 - validated for flow cytometry by staining human PBMCs. Flow plot shown on vendor's website. 
Biotin anti-mouse B220 - validated by flow cytometric staining of mouse splenocytes. Flow plot shown on vendor's website. 
Biotin anti-mouse MHC II (I-A/I-E) - validated by flow cytometric staining of mouse splenocytes. Flow plot shown on vendor's 
website. 
Biotin anti-mouse CD4 - validated by flow cytometric staining of mouse splenocytes. Flow plot shown on vendor's website. 
Biotin anti-mouse CD49b - validated by flow cytometric staining of mouse splenocytes. Flow plot shown on vendor's website. 
Biotin anti-mouse CD11b - validated by flow cytometric staining of mouse bone marrow cells. Flow plot shown on vendor's 
website. 
Anti-mouse CD3e - validated by flow cytometric staining of mouse splenocytes. Flow plot shown on vendor's website. 
Anti-mouse CD28 - validated by flow cytometric staining of mouse thymocytes. Flow plot shown on vendor's website. 
BV605 anti-human CD45 - validated for flow cytometry by staining mouse bone marrow cells. Flow plot shown on vendor's 
website. 
BV785 anti-human CD326 (EpCAM) - validated for flow cytometry by staining human colon carcinoma cell line HT29.Flow plot 
shown on vendor's website  
APC Fire 750 anti-human CD31 - validated for flow cytometry by staining human PBMCs. Flow plot shown on vendor's website. 
PE/Cy7 anti-human CD140a (PDGFRA) - validated for flow cytometry by staining human PDGFRA transfected NIH/3T3 cells. Flow 
plot shown on vendor's website. 
APC anti-human CD49e (ITGA5) - validated for flow cytometry by staining human PBMCs. Flow plot shown on vendor's website. 
PE anti-human CD9 - validated for flow cytometry by staining human PBMCs. Flow plot shown on vendor's website.
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) MDCK cells were obtained from ATCC.
Authentication MDCK cells were authenticated by ATCC
Mycoplasma contamination Cells were not tested for mycoplasma contamination. 
Commonly misidentified lines
(See ICLAC register)
Commonly misidentified cell lines were not used in this study.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals Mice used in this study were age- and sex-matched (8 - 12 weeks old). C57BL6/J and B6.129P2-Adamts4tm1Dgen/J , which were 
back-crossed for at least 10 generations with in-house bred C57BL6/J mice, were used in this study. Cages, water bottles, and 
food for animals were sterilized by autoclave before use. ABSL2 rooms were kept under negative pressure with a ventilation 
system providing HEPA-filtered outside air. Average temperature in the housing rooms was 68 degrees F, and humidity was 
approximately 45%. Light cycle was 12 hours light/12 hours dark.
Wild animals This study did not involve wild animals.
Field-collected samples This study did not involve samples collected from the field.
Ethics oversight Studies involving mice were approved by the St. Jude Children’s Research Hospital Committee on Care and Use of Animals.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Human research participants
Policy information about studies involving human research participants
Population characteristics Co-variate relevant population characteristics are presented in Figure 4 and Supplemental Tables 3, 4, 5, and 6.
Recruitment This study involved samples from three distinct human cohorts. Samples were collected as a part of the care of the patients. For 
the PICFLU cohort, children were excluded if they had an underlying condition predisposing them to severe influenza virus 
infection as the focus of the study was on otherwise healthy individuals. Patients were approached for participation in the study 
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following admission to the hospital, and we do not anticipate self-selection biases for recruitment into the study.
Ethics oversight For the PICFLU cohort, the study was approved by the lead site Boston Children’s Hospital (IRB X08-11-0534) and then at each 
enrolling site’s IRB (enrolling sites are listed in acknowledgments) and written informed consent was obtained from at least one 
parent or guardian. 
 
For the Guangzhou cohort, the study was approved by the ethics committee of the First Affiliated Hospital of Guangzhou Medical 
University (No: 2016-78), and informed consent was obtained from all patients or their guardians. 
 
For the Taiwan cohort, the human subjects’ protocol was reviewed and approved by the Johns Hopkins School of Medicine and 
the Chang Gung Memorial Hospital Institutional Review Boards (IRB00091667). Informed consent was obtained from all patients 
or their guardians. 
 
For lung samples from de-identified, deceased donors, the tissues utilized were procured by the National Disease Research 
Interchange (NDRI) with support from NIH grant U42OD11158. All NDRI consent forms and protocols are reviewed and approved 
by the Institutional Review Board at the University of Pennsylvania. Research involving these tissues was determined to not 
involve human subjects by the Institutional Review Board at St. Jude Children’s Research Hospital. 
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Flow Cytometry
Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation For mouse lung samples, lungs were perfused with 10 mL of cold 1x PBS injecting into the right ventricle of the heart and then 
minced and digested in lung digestion buffer containing 400 U/mL of Collagenase I (Worthington Biochemical Corporation) and 
50 U/ml of DNaseI (ThermoFisher) in Hanks Balanced Salt Solution (HBSS) for 75 minutes at 37 degrees C. Digested lungs were 
filtered through a 100 μm cell strainer and washed with HBSS. Red blood cell lysis was performed 
Instrument BD LSRFortessa
Software Data Collection: BD FACSDIVA software Version 8.0.1 
Data Analysis: FlowJo 10.4.2
Cell population abundance Frequency and total cell numbers of cell populations are indicated in the figures. Cells were counted using a Vi-CELL XR cell 
counter (Beckman Coulter). Viability of cell samples was determined using Ghost Dye Violet 510 (TONBO).
Gating strategy Preliminary gates based on FSC and SSC were drawn to identify all cells. FSC-H vs. FSC-A or SSC-H vs. SSC-A were then used to 
identify single cells. For all experiments, Ghost Dye Violet 510 was used to identify live cells. For downstream gating of CD45- and 
CD45+ populations, gates were drawn according to the strategy presented in the supplementary figures and figure legends. 
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
